- Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
- Nearly 160 Million Americans Harmed by Another’s Drinking, Drug Use
- 1 in 4 Americans Now Struggling to Cover Medical Costs
- Getting Fitter Can Really Help Keep Dementia at Bay
- Skin Patch Could Monitor Your Blood Pressure
- There May Be a Better Way to Treat Hematoma Brain Bleeds
- Chronic Joint Pain Plus Depression Can Take Toll on the Brain
- Living in Space Won’t Permanently Harm Astronauts’ Thinking Skills
- Kids’ Injuries in Sports and at Home: When Is It Right to Seek Medical Attention?
- Human Cell Atlas Will Be ‘Google Maps’ for Health Research
Lawsuit Against Makers of Ozempic, Mounjaro Claim Meds Caused ‘Stomach Paralysis’
A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk of severe stomach problems.
The lawsuit seeks “very significant” but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Fla.-based firm Morgan & Morgan.
Pennock filed the lawsuit Wednesday on behalf of Jaclyn Bjorklund, 44, NBC News reported.
The lawsuit against Novo Nordisk and Eli Lilly claims Bjorklund was “severely injured” after taking the two diabetes drugs, which are part of a new class of medication called GLP-1 agonists.
Pennock said she is suffering “persistent” vomiting and severe gastroparesis, also known as stomach paralysis.
Gastroparesis slows or stops food from moving out of the stomach and into the small intestines. It can be caused by underlying medical issues, including diabetes, according to the American College of Gastroenterology. Infections and some medication can also cause it.
The GLP-1 agonists slow food’s movement and have been found to cause some GI issues in clinical trials. Those are listed as side effects on the drug labels.
Both Ozempic and Mounjaro have the phrase “delays gastric emptying” on their prescribing information, though they don’t specifically use the word “gastroparesis,” NBC News reported.
A U.S. Food and Drug Administration spokeswoman said it was unclear whether the GLP-1 medications contribute to gastroparesis.
“If newly identified safety signals are identified, the FDA will determine what actions are appropriate after a thorough review of the body of evidence,” spokeswoman Chanapa Tantibanchachai said in a statement.
Eli Lilly did not respond to an NBC News request for comment, and a Novo Nordisk spokeswoman said the company was unaware of the lawsuit.
“Patient safety is of utmost importance to Novo Nordisk,” said spokeswoman Natalia Salomao. “We recommend patients take these medications for their approved indications and under the supervision of a health care professional.”
More information
There’s more about GLP-1 agonists and weight loss at the Mayo Clinic.
SOURCE: NBC News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.
Related
-
-120x134.jpg)
More Hot Flashes Could Mean Higher Odds for Type 2 DiabetesMenopausal women with frequent hot flashes and night sweats...
- November 4, 2024
-
Late-Life Menopause Linked to Higher Asthma RiskWomen who enter menopause at a later age have...
- October 30, 2024
-
Biden Proposes That Insurers Cover Over-the-Counter Birth ControlHealth insurers would be required to cover the cost...
- October 21, 2024
-
Some IUDs May Raise The Odds for Breast Cancer, But Overall Risk Remains LowIntrauterine devices (IUDs) may raise the chances of a...
- October 18, 2024
-200x224.jpg)
